24-Nov-2020 - Wacker Chemie AG

CureVac and WACKER Sign Manufacturing Contract for CureVac’s COVID-19 Vaccine Candidate

Manufacturing at WACKER’s Biotech Site in Amsterdam is Scheduled to Start in the First Half of 2021

CureVac N.V. and Wacker Chemie AG announced that they had signed a contract for the manufacturing of CureVac’s COVID-19 vaccine candidate CVnCoV.

Under the terms of the initial agreement, WACKER will ramp up GMP (Good Manufacturing Practice) production of the mRNA drug substance for CVnCoV at its biotech site in Amsterdam in the first half of 2021. Preparations for the start of production, technology transfers and test runs are already underway. It is planned to produce more than 100 million doses of the CureVac vaccine per year at WACKER’s Amsterdam site. There is also further potential for expansion at the site in order to meet rising demand in the future.

WACKER’s CEO Rudolf Staudigl said: “We are proud and highly motivated to make a contribution to the fight against the spread of the coronavirus pandemic together with CureVac.” As a CDMO (Contract Development and Manufacturing Organization), Wacker Biotech bundles WACKER Group’s biopharmaceutical activities. Its Amsterdam site has been producing vaccines for clinical development and commercial supply for 20 years. The portfolio ranges from conventional live and killed vaccines to protein-based, polysaccharide and glycoconjugate vaccines. In recent months, WACKER has invested in the site to extend production to include mRNA-based vaccines. This new class of vaccines expands the broad vaccine portfolio Wacker Biotech offers to its customers.

Dr. Florian von der Mülbe, Chief Production Officer of CureVac, added: “With WACKER, we have found a committed and highly experienced partner for the production of our vaccine candidate in the Netherlands.” CureVac is building an integrated European vaccine manufacturing network with several CDMO partners. With this strategy, the company will significantly increase the manufacturing capacity already existing within CureVac for CVnCoV up to several hundred million doses per year and will manage potential supply chain risks by working with several partners for each of the key manufacturing process steps.

Facts, background information, dossiers
  • CureVac
  • Wacker Chemie
  • Covid-19
  • mRNA vaccines
More about Wacker
  • News

    WACKER Strengthens Biologics Business by Acquiring US-Based Plasmid DNA Manufacturer Genopis

    The Munich-based chemical company WACKER is acquiring 100 percent of the shares in pharmaceutical contract manufacturer Genopis Inc. from Helixmith Co Ltd, Seoul (South Korea) and Medivate Partners LLC, Seoul (South Korea). WACKER signed a corresponding agreement. WACKER will continue Genop ... more

    WACKER Invests in Amsterdam Biotech Site

    WACKER, the Munich-based chemicals Group, is investing in its production facilities for biologics, LMPs (live microbial products) and vaccines at its Amsterdam site. Projects include the construction of a new fermentation line with a volume of 1,500 liters as well as the setting up of new c ... more

    SynCo Bio Partners B.V. is Now Wacker Biotech B.V.

    As of November 1, 2018, the pharmaceutical protein production facility in the Netherlands acquired by WACKER with its takeover of SynCo Bio Partners Luxembourg S.à r.l., will be renamed Wacker Biotech B.V. The site in Amsterdam for the manufacture of biopharmaceuticals, live microbial produ ... more

  • Companies

    Wacker Biotech GmbH

    more

    Wacker Biotech B.V.

    SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with clinical and commercial production experience with mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producin ... more

More about CureVac